<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177670</url>
  </required_header>
  <id_info>
    <org_study_id>S0210001</org_study_id>
    <nct_id>NCT01177670</nct_id>
  </id_info>
  <brief_title>Adiana Post-Approval Clinical Study (APACS)</brief_title>
  <acronym>APACS</acronym>
  <official_title>Adiana Post-Approval Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hologic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hologic, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Adiana Post-Approval Clinical Study (APACS) has been designed to compile information on
      the efficacy and safety of the Adiana Permanent Contraception System in the post market
      setting. Specifically, data will be collected that is relevant to the evaluation of the
      safety and efficacy of the Adiana System for women who desire permanent birth control by
      occlusion of the fallopian tubes. This study is an observational study that is not intended
      to test specific hypotheses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adiana Post-Approval Clinical Study is a prospective, single armed, multi-center,
      observational study that is designed to provide additional efficacy and safety data regarding
      the FDA-approved Adiana Permanent Contraception System. This study will be conducted at 8-10
      clinical sites and enroll 1000 subjects. Enrolled subjects will have baseline data collected
      at the time of their Adiana procedure and will then be followed for a period of 2 years with
      visits occurring at 3 months following the Adiana procedure, 6 months following Adiana
      procedure (as applicable), 12 and 24 months post relying date.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Hologic made business decision to no longer sell or manufacture Adiana device.
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy Rate - for Women Informed They May Rely on the Adiana System for Contraception.</measure>
    <time_frame>At one and two years</time_frame>
    <description>The primary efficacy endpoints are the one and two year pregnancy rates among women who have hysterosalpingogram (HSG)-proven bilateral occlusion and are informed that they may rely on the Adiana System for contraception.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>At one and two years</time_frame>
    <description>The Adiana System will be evaluated for safety on the basis of the occurrence of adverse events which are related to the study device, unanticipated or serious.</description>
  </secondary_outcome>
  <enrollment type="Actual">169</enrollment>
  <condition>Women Contraception</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Women, 18 - 45 years old, at risk for pregnancy, that are seeking permanent contraception
        using the Adiana Permanent Contraception System.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are seeking permanent sterilization

          -  Women 18-45 years old

          -  Subjects who are at risk of becoming pregnant

          -  Subjects willing to use alternative contraception for at least three (3) months
             following device placement and bilateral tubal occlusion is confirmed by HSG

          -  Subjects who are able to provide informed consent

        Exclusion Criteria:

          -  Subjects who are uncertain about their desire to end fertility

          -  Clinical evidence of an active pelvic infection or history of a recent pelvic
             infection

          -  Has intra-uterine pathology which would prevent access to either tubal ostium or the
             intramural portion of either fallopian tube (i.e., large submucous fibroids, uterine
             adhesions, apparent uni or bilateral proximal tubal occlusion, suspected unicornuate
             uterus, etc.)

          -  Is pregnant (as evidenced by pregnancy test result) or suspects pregnancy

          -  Is currently less than three (3) months since her last pregnancy

          -  Has previously undergone a tubal ligation

          -  Is currently taking immunosuppressive medication (e.g., steroids)

          -  Has a known allergy to contrast media

          -  Has external pacemaker or internal cardioverter defibrillator

          -  Subject is unable to follow the protocol and return for follow up visits

          -  In the opinion of the investigator, the subject has a medical condition that precludes
             safe participation in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Evantash, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hologic, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sutter Medical Group</name>
      <address>
        <city>Elk Grove</city>
        <state>California</state>
        <zip>95758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WomenCare, P.C.</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Care</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valaoras &amp; Lewis Obstetrics and Gynecology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complete Healthcare for Women</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Women's Center of Central Oregon</name>
      <address>
        <city>Redmond</city>
        <state>Oregon</state>
        <zip>97756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salem Women's Clinic</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ob/Gyn Associates of Danville</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <results_first_submitted>September 18, 2012</results_first_submitted>
  <results_first_submitted_qc>October 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2012</results_first_posted>
  <last_update_submitted>October 19, 2012</last_update_submitted>
  <last_update_submitted_qc>October 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adiana Permanent Contraception System</keyword>
  <keyword>women seeking permanent sterilization.</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was designed to be conducted at 8-10 clinical sites and enroll 1000 subjects.Enrolled subjects were to have baseline data collected at the time of their procedure and then be followed for 2 years with visits occurring at 3 months following the procedure, 6 months following the procedure, 12 and 24 months post relying date.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Enrolled</title>
          <description>All subjects who met enrollment inclusion/exclusion criteria, signed informed consent form, had baseline data collected and Adiana procedure performed or attempted.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Terminated</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enrolled</title>
          <description>All subjects who met enrollment inclusion/exclusion criteria, signed informed consent form, had baseline data collected and Adiana procedure performed or attempted.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="169"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.8" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pregnancy Rate - for Women Informed They May Rely on the Adiana System for Contraception.</title>
        <description>The primary efficacy endpoints are the one and two year pregnancy rates among women who have hysterosalpingogram (HSG)-proven bilateral occlusion and are informed that they may rely on the Adiana System for contraception.</description>
        <time_frame>At one and two years</time_frame>
        <population>Efficacy results were not tabulated due to the early termination of the study. Only 169 of the planned 1,000 subjects (16.9%) were enrolled therefore the study is defined as incomplete, as fewer than one-third of the intended patients were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled</title>
            <description>All subjects who met enrollment inclusion/exclusion criteria, signed informed consent form, had baseline data collected and Adiana procedure performed or attempted.</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Rate - for Women Informed They May Rely on the Adiana System for Contraception.</title>
          <description>The primary efficacy endpoints are the one and two year pregnancy rates among women who have hysterosalpingogram (HSG)-proven bilateral occlusion and are informed that they may rely on the Adiana System for contraception.</description>
          <population>Efficacy results were not tabulated due to the early termination of the study. Only 169 of the planned 1,000 subjects (16.9%) were enrolled therefore the study is defined as incomplete, as fewer than one-third of the intended patients were enrolled.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoints</title>
        <description>The Adiana System will be evaluated for safety on the basis of the occurrence of adverse events which are related to the study device, unanticipated or serious.</description>
        <time_frame>At one and two years</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled</title>
            <description>All subjects who met enrollment inclusion/exclusion criteria, signed informed consent form, had baseline data collected and Adiana procedure performed or attempted.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoints</title>
          <description>The Adiana System will be evaluated for safety on the basis of the occurrence of adverse events which are related to the study device, unanticipated or serious.</description>
          <population>Intent to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Event Related to Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious and Related Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Enrolled</title>
          <description>All subjects who met enrollment inclusion/exclusion criteria, signed informed consent form, had baseline data collected and Adiana procedure performed or attempted.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <description>The serious adverse event was a diagnosis of hepatitis C that was moderate in severity, not related to the device, required outpatient treatment, and was ongoing at the termination of the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>4 subjects reporting nausea (nausea and post op nausea)</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain or Cramping</sub_title>
                <description>56: abdominal cramping, abdominal pain, cramping, left lower quadrant pain, moderate pain, pelvic cramping, pelvic cramps, pelvic pain, pelvic pain and strain, post op abdominal pain, post op pain and/or post procedureâ€“mild pelvic pain</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <description>5 subjects reporting pregnancy. 1 occurred prior to confirmation the subject could rely on Adiana.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>There were 33 subjects experiencing bleeding-related adverse events (abnormal vaginal bleeding, light bleeding, moderate bleeding, scant bleeding, scant blood, scant vaginal bleeding, spotting, and/or vaginal bleeding).</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>After determining Adiana was not financially viable and would not become so, Hologic decided to discontinue manufacturing &amp; sales. Hologic decided to terminate the study. All subjects were notified of termination and withdrawn by April 30, 2012.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Edward Evantash, MD</name_or_title>
      <organization>Hologic, Inc.</organization>
      <phone>508-263-8475</phone>
      <email>edward.evantash@hologic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

